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Introduction 
Extracellular vesicles (EVs) refer to all endogenously pro-
duced membrane-bound vesicles that are released from 
cells into the extracellular space [1]. EVs contain various 
molecules, such as DNA, messenger RNA (mRNA), proteins, 
Extracellular vesicles (EVs), such as exosomes and microvesicles, are cell-derived lipid bilayer membrane particles, which deliver in-
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lipids, and microRNAs (miRNAs). Different subtypes of EVs 
have been described including exosomes, microvesicles 
or microparticles, apoptotic bodies, ectosomes, and onco-
somes based on their origin, size, contents, and biogenesis 
(Table 1). In the narrow sense, EVs usually refer to exosomes 
or microvesicles. In this review, we will use the compre-
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hensive term ‘EVs’ to focus on exosomes and microvesicles 
because of overlapping characteristics among the different 
subtypes. EVs were initially discovered over 30 years ago, 
but it was thought that their physiological role was limited 
to the excretion of intracellular or membrane components 
of cells. However, recent advancements have shown that 
EVs are involved in multiple biological processes such as 
immune modulation, hemostasis, and tissue proliferation/
regeneration, which can affect the development and regen-
eration of organs [1–3]. EVs are also widely found in patho-
logic conditions. Their presence in any body fluid expands 
the diagnostic role of EVs as biomarkers in various types 
of diseases. EVs also contribute to disease progression by 
affecting the level of inflammation, thrombosis, and tumor-
igenesis [4,5]. On the other hand, EVs have received a lot of 
medical attention as a potential therapeutic vehicle based 
on their capacity of shuttling proteins and genetic materi-
als. In this review, we will focus on the role of EVs in renal 
physiology and disease processes as well as their potential 
applicability as diagnostics and therapeutics in multiple re-
nal diseases. 
Physiologic role of extracellular vesicles in kidneys 
In physiologic conditions, the major biological functions of 
EVs are to get rid of unwanted substances from host cells. 
EVs can also transfer important biological information to 
their recipient cells by delivering genetic material, proteins, 
lipids, and receptors. The conveyance of RNAs or miRNAs 
can have a substantial effect on the recipient cells by re-
programming their genetic characteristics. Below, we will 
discuss in detail the biological function of EVs in renal phys-
iology (Fig. 1A [6]). 
Homeostasis and cell survival 
One of the most important biological roles of EVs is in the 
removal of intracellular toxic materials to extracellular spac-
es. As cells go through multiple biological processes, they 
build up damaged organelles and cellular waste, which can 
induce cellular stress leading to cell death or inflammation. 
Eukaryotic cells have developed a self-defense mechanism 
for the removal of intracellular waste—the secretion of EVs 
into the extracellular space [7]. In this way, cells can effec-
tively eliminate potentially harmful chromosomal DNA 
fragments through exosomes. The inhibition of this process 
can induce an innate immune response, DNA damage, and 
apoptosis in normal human cells. Kidney cells are relatively 
susceptible to biological stress. Under hypoxic conditions, 
renal tubular cells proactively augment the amount of exo-
some secretion and alter the composition of exosomes to 
meet specific biological needs [8]. EV uptake into recipient 
cells is also a very important biological process in intercel-
lular communication. The most common mechanism of 
cellular uptake is endocytosis whereby the EVs are engulfed 
by recipient cells [9]. The balance between EV release and 
uptake depends on the physiologic condition of the parent/
recipient cells, the type of parent/recipient cells, and the 
recognition of ligands/ receptors on the EVs and recipient 
cells [10]. 
Inflammation/immunomodulation 
EVs are a miniature version of their parent cells, so their 
immunologic function significantly depends on their origin 
and the microenvironment their parent cells are exposed 
to. For example, EVs from dendritic cells can function as 
Table 1. Classification of extracellular vesicles
Variable Exosome Microvesicle Apoptotic body
Formation Endosomal pathway, exocytosis Outward blebbing of the plasma 
membrane
Cell shrinkage and fragmentation
Size 30–100 nm 100–1,000 nm 1–5 µm
Content Proteins, lipids, mRNA, miRNA, and 
cytosol
Proteins, lipids, mRNA, miRNA, and 
cytosol
Proteins, lipids, nuclear fractions, 
DNA, rRNA, organelles, and cytosol
Main protein markers Tetraspanins (CD63, CD9), Alix, and 
TSG101
Integrins, selectins, and CD40 ligand Histones
Appearance by electron 
microscopy
Cup shape Irregular shape Heterogenous
mRNA, messenger RNA; miRNA, microRNA; rRNA, ribosomal RNA; TSG101, tumor susceptibility gene 101.
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antigen-presenting vesicles through the direct presentation 
of peptide-major histocompatibility complex (MHC) com-
plexes to T cells [11]. These peptide-MHC complexes can 
be transferred to other recipient cells, indirectly presenting 
antigens, and subsequently leading to immune cell stimu-
lation. On the other hand, EVs secreted by tumor cells can 
mediate an immuno-suppressive response by switching 
monocytes and T cells to tolerogenic subtypes, inhibiting 
the differentiation of monocytes, or inducing the apoptosis 
of bystander T cells, so-called activation-induced cell death 
[12]. The physiological state of the parent cells significantly 
affects the content of the EVs. For example, exosomes de-
rived from hypoxic tumor cells could induce higher levels 
of differentiation and the activation of myeloid-derived 
suppressor cells compared to exosomes derived from cells 
under normoxic conditions [13]. 
Antimicrobial effect 
The urinary tract system is constantly exposed to microor-
ganisms from the exterior environment, putting it at high risk 
of urinary tract infection. However, most of the urinary tract, 
except the urethra, generally remains sterile. This resistance 
to infection is mediated by several factors. Traditionally, ana-
tomical barriers, such as the glycoprotein plaque and a layer 
of hydrated mucus, as well as immunologic barriers from 
various resident immune cells and the epithelial cell lining, 
were considered to be major host defense mechanisms [14]. 
Recently, EVs were found to serve a significant role against 
infection within the urinary tract. A proteomic study showed 
that enriched innate immune proteins including calprotectin 
and lysozyme C in urinary EVs could mediate an antimicro-
bial effect [15]. Even though autophagy is a well-developed 
cellular defense mechanism to clear foreign pathogens, some 
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Figure 1. Role of extracellular vesicles (EVs) in normal kidneys and renal disease. (A) EVs mediate cell-to-cell communications, 
modulating cellular homeostasis, electrolyte/water balance, tubular regeneration, and inflammatory reactions in normal kidneys. (B) 
EVs affect disease progression by amplifying inflammation, inducing tubulointerstitial fibrosis or glomerular epithelial-mesenchymal 
transition (EMT). EVs may also be involved in the pathogenesis of renal cell carcinoma (RCC) and renal allograft rejection.
Ag, antigen; CD, collecting duct; DC, dendritic cell; DT, distal tubule; ENaC; epithelial sodium channel; PT, proximal tubule; TEC, tubular 
epithelial cells.
Modified from the article of Kwon et al. (Korean J Intern Med 2019;34:470-479) [6] under the Creative Commons License.
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bacteria have evolved defense mechanisms to overcome 
autophagy by neutralizing lysosomal pH. A study by Miao 
et al. [16] shows that bladder epithelial cells can overcome 
this phenomenon through exosomes—by expulsing exo-
some-encased bacteria from the intracellular space. 
Kidney regeneration/repair 
Mesenchymal stem cells (MSCs) are well-known for their 
regenerative and reparative potential in different organs in-
cluding the kidneys [17]. However, the reparative potential 
of MSCs is mediated through EVs rather than the differen-
tiation potential of the MSCs themselves. MSC-derived EVs 
contain different types of antioxidants and growth factors 
to stimulate the differentiation of resident progenitor cells. 
Delivery of genetic materials like DNA, miRNAs, or mRNAs 
through EVs can also introduce the reparative potential of 
parental MSCs to recipient cells. In a study by Ranghino et 
al. [18], glomerular MSC-derived EVs mediated tubular ep-
ithelial cell regeneration and alleviated ischemic acute kid-
ney injury (AKI) by transferring mRNAs and miRNAs with 
potential proregenerative effects. 
Hemostasis and platelet aggregation 
An ample number of publications have reported the coagu-
lant properties of plasma EVs in humans [19,20]. EVs originat-
ing from platelets, endothelial cells, or leukocytes were found 
to be involved in the course of hemostasis. These EVs can ini-
tiate the coagulation process by exposing phosphatidylserine 
(PS) on their surfaces to allow binding sites for coagulation 
factors [21]. Another mechanism is through the expression 
of tissue factors on their surfaces, initiating the extrinsic 
pathway of coagulation and leading to thrombin burst and 
platelet clot formation [22]. A study by Yu et al. [23] showed 
that patients with diabetic kidney disease had a significantly 
higher level of PS-expressing microvesicles compared to con-
trol groups. They also found that higher levels of PS-positive 
microvesicles were associated with hypercoagulable status as 
well as worse renal function. A similar finding was shown in 
patients with immunoglobulin A nephropathy [24]. 
Recently, several studies have revisited the procoagulation 
property of EVs because of technical improvements in blood 
collection, plasma preparation, and EV isolation [25]. Inter-
estingly, plasma EVs isolated from healthy individuals pro-
mote fibrinolysis more dominantly than coagulation. This 
discrepancy suggests an ambivalent role of EVs in hemosta-
sis processes, which depends on the microenvironment. In 
addition, proper EV sample preparation is important for a 
better understanding of their role in the human body. 
Vessel integrity and revascularization 
Endothelial cell-derived EVs help to maintain vessel integri-
ty and promote vascular endothelial cell survival by remov-
ing cell-death signals and releasing excess complements 
from vascular endothelial cells [26]. In damaged vessels, 
platelet-derived EVs induce the adhesion of endothelial cells 
to the extracellular matrix, which helps the regeneration of 
endothelium and attenuates vascular permeability [27]. 
Tumor-derived EVs are well-known for their angiogene-
tic properties, but EVs can also induce angiogenesis under 
physiologic conditions. Endothelial cell-derived EVs modu-
late angiogenesis by promoting endothelial cell invasion and 
capillary-like structure formation [28]. Recently, the transfer 
of certain miRNAs, including miR-126 or miR-124, using en-
dothelial cell-derived EVs and recipient endothelial cells has 
been found to have a significant role in angiogenesis [29,30]. 
MSC-induced EVs also induce angiogenesis by transferring 
proteins like phosphorylated signal transducer and activator 
of transcription-3 or nuclear factor-kB pathway-associat-
ed proteins, leading to the transcription of proangiogenic 
proteins [31,32]. MSC-derived EVs can also transfer several 
growth factors including epidermal growth factor and vascu-
lar endothelial growth factor to endothelial cells promoting 
angiogenesis. More detailed information about the angioge-
netic mechanism of EVs from multiple cellular origins can 
be found in a review article by Todorova et al. [2]. 
Electrolyte and water balance 
Sodium/water reabsorption is one of the major functions 
of renal tubular cells. Two-thirds of filtrated sodium is reab-
sorbed in proximal tubular epithelial cells and fine-tuning 
for sodium reabsorption occurs in the distal tubule and col-
lecting ducts. Therefore, interactive communication between 
proximal and distal/collecting tubular cells are important for 
proper maintenance of electrolyte balance and volume con-
trol. A study by Jella et al. [33] showed that exosomes from 
proximal tubular cells can regulate epithelial sodium channel 
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activity in the distal tubule and collecting ducts through the 
exosomal delivery of glyceraldehyde 3-phosphate dehydro-
genase. Upon exposure to vasopressin, cortical collecting 
duct tubular cells increase the production of aquaporin 
water channels within themselves as well as within their 
exosomes [34]. These exosomes could transfer functional 
aquaporin channels to other tubular cells, increasing their 
water transport capacity. By mediating inter and intracel-
lular communication of renal epithelial cells among the 
different nephron segments, exosomes provide a significant 
role in electrolyte and fluid balance in the human body. 
Extracellular vesicles as mediators of kidney 
disease 
In pathologic conditions, the production of EVs significantly 
increases, contributing to the initiation and propagation of 
disease through immunomodulation, thrombogenesis, and 
oncogenesis. The detailed role of renal EVs in different dis-
ease courses are discussed below (Fig. 1B). 
Glomerular disease 
In advanced glomerular disease, tubular damage and fi-
brosis are the leading mechanisms of renal dysfunction. A 
recent study by Jeon et al. [35] showed that miRNAs in EVs 
released by injured podocytes can induce tubular epithe-
lial cell apoptosis, suggesting possible glomerulotubular 
crosstalk. This study also showed that the miRNA profile 
in EVs from injured podocytes are different from those 
of non-injured podocytes, and miRNA mimics of injured 
podocytes could reproduce a proapoptotic effect on renal 
tubular epithelial cells. In diabetic nephropathy, exposure 
to high glucose levels can induce EV production from 
podocytes. Tubular epithelial cells uptake these podo-
cyte-derived EVs and generate tubular fibrosis through 
p38 phosphorylation [36]. 
Acute kidney injury 
A recent miRNA sequencing study showed that urinary 
exosomal miRNAs have characteristic profiles and func-
tional properties that depend on the AKI stage [37]. Sev-
eral exo-miRNAs (miR-16, miR-24, and miR-200c) were 
increased during the early injury state, and the expression 
of their target mRNAs was significantly affected in the renal 
medulla. During the early recovery phase, exo-miRNAs that 
share Zeb1/2 as a common target were significantly upreg-
ulated, implying their role in transforming growth factor 
(TGF)-β1-associated renal fibrosis. In ischemia-reperfusion 
injury, hypoxic damage induces the increased production of 
EVs in tubular epithelial cells that contains TGF-β1 mRNA [8]. 
Exosomal delivery of these TGF-β1 mRNAs into fibroblasts 
ultimately leads to fibroblast activation and proliferation. 
On the other hand, Ranghino et al. [18] recently showed that 
MSCs within the glomeruli can contribute to postischemic 
renal recovery primarily through the release of EVs. 
In sepsis-related AKI, platelet-derived and neutrophil-de-
rived EVs demonstrate proinflammatory and procoagulant 
effects, which can prevent the growth of bacteria and its 
dissemination [38]. However, these EVs can systematically 
induce oxidative stress and disseminate inflammatory re-
sponses, leading to poorer clinical outcomes.  
Tubulointerstitial inflammation 
Tubulointerstitial inflammation is a common characteristic 
of both acute and chronic kidney disease. Lv et al. [39] found 
a significant increase in tubular epithelial cell-derived exo-
somal miRNA-19b-3p in both a lipopolysaccharide-induced 
AKI model and an adriamycin-induced chronic proteinuric 
kidney disease model. Tubular epithelial cell-derived exo-
somal miRNA-19b-3p promoted M1 macrophage activa-
tion and tubulointerstitial inflammation. This group also 
showed that exosomal delivery of CCL2 mRNA from tubular 
epithelial cells to macrophages could mediate albumin-in-
duced tubulointerstitial inflammation [40]. Hypoxia is 
another well-known stimulator of tubulointerstitial inflam-
mation in the kidney. Hypoxic stimulation induces the ex-
pression of hypoxia-inducible factor-1α in tubular epithelial 
cells. This stimulus leads to exosomal miRNA-23a transfer 
from tubular epithelial cells to macrophages, which triggers 
macrophage activation and promotes tubulointerstitial in-
flammation [41]. Thus, modulation of macrophage activa-
tion by blocking exosomal miRNA or mRNA delivery from 
tubular epithelial cells can be a novel therapeutic approach. 
Fibrosis 
Fibrosis in glomeruli and tubules is an ultimate pathologic 
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process of chronic kidney diseases and end-stage renal dis-
ease, and the pathophysiological role of EVs in fibrosis has 
been explored in several studies [5,8,42,43]. Various stimuli 
on renal cells, such as hypoxia, oxidative stress, or high 
glucose, can lead to EV secretion or changes in the EV com-
position [8,42]. EVs secreted by damaged kidney cells can 
be transferred to other normal kidney cells, changing their 
phenotype and activating fibroblasts. In hypoxic conditions, 
damaged tubular epithelial cells transfer TGF-β1 mRNA to 
fibroblasts through exosome secretion, ultimately leading 
to the proliferation/activation of fibroblasts and progression 
of renal tubular fibrosis [8]. An in vitro study by Wu et al. 
[42] showed that EVs secreted from high glucose-treated 
glomerular endothelial cells can trigger podocyte epitheli-
al-mesenchymal transition by transferring TGF-β1 mRNA 
into glomerular mesangial cells. This process induces cellu-
lar proliferation and overproduction of extracellular matrix 
within glomeruli, which is a key pathological mechanism 
of diabetic nephropathy. Several miRNAs in EVs, such as 
miR-21, miR-192, and miR-34a, also affect the biological 
processes of tubular fibrosis [43,44] and glomerular fibrosis 
[45], respectively. 
Nephrolithiasis 
Given the significant role of EVs as mediators of various re-
nal diseases, several studies have speculated that EVs have 
a role in stone formation. For instance, an in vitro study by 
He et al. [46] showed that exposure of renal tubular cells to 
different concentrations of oxalates could affect the size and 
composition of the exosomes from tubular cells. This result 
suggests that the biological role of exosomes may depend 
on the level of oxalate exposure in a given microenviron-
ment. Other in vitro studies by Singhto et al. [47,48] showed 
that exosomes derived from human macrophages exposed 
to calcium oxalate crystals could induce the migration/
activation of monocytes/T-cell/neutrophils and enhance 
the production of proinflammatory cytokine interleukin-8. 
These exosomes had a greater capacity to bind calcium ox-
alate crystals and subsequently enhanced crystal invasion 
through the extracellular matrix, suggesting the possible 
role of macrophage-derived exosomes in the crystal inva-
sion of the renal interstitium. 
Renal cancer 
EVs mediate intercellular communication between tumor 
cells. EVs from cancer cells contain proangiogenic mRNAs 
and various miRNAs with tumor invasive properties [49]. 
Clear renal cell carcinoma-derived EVs can negatively affect 
adjacent immune cells by the activation of the TGF-β/SMAD 
signaling pathway [50]. EVs are also known to mediate che-
moresistance in renal cancer cells through the delivery of 
long noncoding/competing endogenous RNA, ultimately 
leading to higher expression of prometastatic receptors [51]. 
Further information about the role of EVs in urological ma-
lignancies is well described in a review article by Linxweiler 
and Junker [4].  
Extracellular vesicles as biomarkers in various 
kidney diseases 
Most of the EV studies in kidney diseases have been focused 
on biomarker discoveries. EVs can be found in multiple 
types of biological fluids including serum, urine, breast 
milk, cerebrospinal fluid, saliva, ascites, and bronchoalve-
olar lavage fluid. Under physiologic conditions, almost all 
urinary EVs originate from kidney cells because circulating 
EVs do not generally go through the glomerular basement 
membrane. Therefore, the organ-specific origin of urinary 
EVs comprises the major advantage of using urinary EVs 
as biomarkers in kidney diseases. Also, urinary EVs can be 
obtained noninvasively and repeatedly, providing important 
information regarding diagnosis, prognosis, and response to 
treatment. 
Even though circulating EVs can originate from different 
organs, serum, and plasma, they can still provide significant 
information about the extent and prognosis of renal disease 
because the clinical outcome is determined not only from 
the kidney damage itself but also from the dysfunction of 
distant organs including the lungs, heart, brain, liver, and 
immune system [52]. Easier clinical accessibility is also a 
huge benefit of using circulating EVs as biomarkers in kidney 
disease. 
Recent advancements in ‘omic’ studies have expedited the 
discovery of novel EV biomarkers enabling the detection of 
pathologic processes even earlier than traditional biomark-
ers. Salih et al. [53] compared urinary EVs from autosomal 
dominant polycystic kidney disease (ADPKD) patients and 
Lee, et al. Extracellular vesicles in kidney diseases
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healthy controls using quantitative proteomics. Among the 
proteins with higher abundancy, five proteins including 
complements and plakins were selected for further analysis 
based on their significance in pathway analysis. Especially, 
a higher level of complement in urinary EVs was found in 
younger ADPKD patients with preserved kidney function, 
raising its potential as a biomarker. Due to the vast amount 
of information from various studies and limited space, the 
role of EVs as biomarkers is summarized in Table 2 [53–78]. 
Extracellular vesicles as therapeutics in various 
kidney diseases 
Extracellular vesicles as a cargo of therapeutic material 
The role of EVs as biocarriers has received a lot of attention 
Table 2. Extracellular vesicles as biomarkers in renal disorders
Disease Source/method Main finding Reference
AKI Human urine/Western blotting Increased level of Na+/H+ exchanger type-3 in urinary exosome was 
found in patients with acute tubular necrosis but not in other etiologies 
of AKI.
[54]
Human or rat urine/proteomics Urinary exosomal Fetuin-A increased with AKI in both humans and rats. 
Exosomal Fetuin-A increase was detectable in the urine even before 
the development of histologic injury.
[55]
Human or rat urine/Western 
blotting
Increased urinary exosomal ATF3 in AKI and WT-1 in podocyte injury. [56]
Human urine/Western blotting Increased urinary exosomal ATF3 in sepsis-induced AKI patients. [57]
DN Human urine/RT-qPCR In DN patients, urinary exosomal let-7c-5p was upregulated, and miR-
29c-5p and miR-15b-5p were down-regulated. These three miRNAs 
could predict the development of DN.
[58]
Human urine/RT-qPCR Increased level of uromodulin mRNA in urinary EVs derived from 
patients with type 2 DM nephropathy compared to type 2 DM without 
nephropathy. Urinary EV uromodulin mRNA level correlates with renal 
function decline in type 2 DM patients.
[59]
Human urine/microarray Type 2 DM patient with microalbuminuria had increased levels of let-7i-
3p, miR-24-3p and miR-27b-3p, and decreased levels of miR-15b-5p. 
The level of miR-30a-5p in urinary EVs was significantly correlated to 
macroalbuminuria in type 2 DM.
[60]
IgA nephropathy Human urine/RT-qPCR Total amount of urinary exosomes and exosomal CCL2 mRNA are 
upregulated in IgA nephropathy patients, which reflects active renal 
histologic injury and renal function deterioration.
[61]
Human serum/RT-qPCR IgA nephropathy patients with lower serum miR-182 had more severe 
tubular atrophy, interstitial inflammation, and fibrotic tendency; IgA 





Exosomal lncRNA-G21551 was significantly down-regulated in IgA 
nephropathy patients compared to healthy first-degree relatives.
[63]
Nephrotic syndrome Human urine/RT-qPCR Urinary exosomal miR-193a is significantly increased in primary FSGS 
patients compared to those in MCD patients.
[64]
Human urine/RT-qPCR Urinary exosomal miR-194-5p, miR-146b-5p, miR-378a-3p, miR-23b-3p 
and miR-30a-5p are significantly increased in nephrotic syndrome and 
markedly reduced during remission. Concentration of miR-194-5p and 




Human urine/Western blotting Patients with delayed graft function after kidney transplantation had 
increased levels of NGAL in urinary exosomes.
[66]
Human plasma/RT-qPCR Increased transcript levels of glycoprotein 130, SH2D1B, TNF-α, and 
CCL4 in plasma exosomes derived from patients with antibody-
mediated rejection.
[67]
Human urine/integrated kidney 
exosome analysis
High level of CD3 positive urinary EVs in patients with acute cellular 
rejection.
[68]
Human urine/proteomics Higher levels of tetraspanin-1 and hemopexin protein are found in 
urinary exosomes derived from patients with T cell-mediated rejection.
[69]
(Continued to next page)
200 www.krcp-ksn.org
Kidney Res Clin Pract 2021;40(2):194-207
PKD Human urine/proteomics Higher levels of complement C3 and C9 are found in urinary EVs derived 
from ADPKD patients.
[53]
Increased levels of villin-1, periplakin, and envoplakin are found in 
urinary EVs from patients with advanced ADPKD.
Human and rat urine/Western 
blotting
Increased urinary exosomal AGS3 expression in PKD patients/rats. [70]
LN Human urine/RT-PCR Urinary exosomal miR-29C correlates with the degree of renal chronicity 
but not with renal function in patients with LN.
[71]
Human urine/RT-PCR Decreased level of urinary exosomal let-7a and miR-21 in patients with 




Urinary exosomes from LN patients complicated with cellular crescent 
have a unique miRNA expression profile including miR-3135b, miR-
654-5p, and miR-146a-5p.
[73]
Renal fibrosis and 
CKD model
Human urine/RT-qPCR Down-regulation of urinary exosomal miR-29c level with worsening renal 
function and progression of tubulointerstitial fibrosis in CKD patients.
[74]
Human and mouse urine/RT-
qPCR
Upregulation of urinary exosomal miR-21 in CKD patients as well as in 
nephrotoxic serum-treated mice.
[75]
Human urine/RNA-sequencing Urinary exosomal miRNA-181a significantly decreased in CKD patients 
compared to healthy controls.
[76]
RCC Human plasma/RT-qPCR Increased hsa-miR-301a-3p and decreased hsa-miR-1293 levels 
were found in plasma EVs in patients with metastatic clear cell RCC 
compared to those with localized disease.
[77]
Human plasma/RT-qPCR Higher levels of plasma EV-derived TIMP-1 mRNA were found in patients 
with metastatic RCC or huge tumor burden. Also, patients with a high 
level of EV-derived TIMP-1 mRNA had poorer survival compared to 
those with a low level.
[78]
ADPKD, autosomal dominant polycystic kidney disease; AGS3, activator of G-protein signaling 3; AKI, acute kidney injury; ATF3, activating transcription 
factor 3; CKD, chronic kidney disease; DN, diabetic nephropathy; DM, diabetes mellitus; EV, extracellular vesicle; FSGS, focal segmental glomerulosclerosis; 
IgA, immunoglobulin A; LN, lupus nephritis; lncRNA, long noncoding RNA; MCD, minimal change disease; miRNA and miR, microRNA; mRNA, messenger 
RNA; NGAL, neutrophil gelatinase-associated lipocalin; PKD, polycystic kidney disease; RCC, renal cell carcinoma; RT-qPCR, reverse transcription-
quantitative polymerase chain reaction; RT-PCR, reverse transcription-polymerase chain reaction; SH2D1B, SH2 domain-containing protein 1B; TIMP, 
tissue inhibitor of metalloproteinase; TNF-α, tumor necrosis factor alpha; WT-1, Wilms tumor 1.
Disease Source/method Main finding Reference
Table 2. Continued
recently. EVs carry several biological benefits as a vector 
over other methods, including stability, small size, and low 
immunogenicity. Specific cell surface molecules on EVs in-
crease their targeting capacity with fewer off-target effects. 
Nanosized EVs with certain surface molecules can even pen-
etrate natural barriers such as the blood-brain barrier [79]. 
Also, EVs use the native mechanisms of recipient cells in the 
course of internalization and intracellular trafficking [80]. 
Delivery of biomolecular cargos such as mRNA, miRNA, 
and proteins can modify the genetic profile and biological 
response of recipient cells, leading to the modulation of dis-
ease processes [81]. 
EV loading of traditional drugs with anti-inflammatory 
properties has been studied for therapeutic applicability 
[82,83]. Dexamethasone, for example, is widely used to sup-
press inflammation in various renal diseases, but its clinical 
use is limited due to significant adverse effects. By incubat-
ing macrophages with dexamethasone, macrophage-de-
rived dexamethasone containing EVs were successfully 
produced and delivered to the inflamed kidneys of mice, 
which showed significant suppression of renal inflammation 
and fibrosis [82]. Notably, dexamethasone containing EVs 
substantially decreased the adverse effects from systemic 
steroid treatment such as hyperglycemia and suppression of 
the hypothalamic-pituitary-adrenal axis. 
During the past decade, there has been an explosive ad-
vancement in EV research. Interdisciplinary cooperation be-
tween medicine and biomedical engineering has harnessed 
EVs as potent drug delivery tools through the application of 
nanotechnology. Several studies have successfully loaded 
genetic material into EVs and shown effects on modifying 
disease courses. Yim et al. [84] recently developed a novel 
technique for the effective intracellular transfer of soluble 
proteins through exosomes by using optogenetic engineering. 
Lee, et al. Extracellular vesicles in kidney diseases
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This technology was adopted in an experimental sepsis model, 
showing the protective effect of exosomal super-repressor in-
hibitor of kappa B (IκB) delivery in a murine septic AKI model 
[85]. Recently, our group has also demonstrated the beneficial 
effect of exosomal super-repressor IκB delivery in an ischemic 
AKI model (under review). 
Extracellular vesicles for kidney repair 
Stem cell therapy has great benefits in multiple experimen-
tal kidney injury models, not through their differentiation 
potential but the paracrine effects of their EVs [17]. EVs se-
creted from MSCs or endothelial progenitor cells have been 
shown to play a significant role in the amelioration of tubular 
cell apoptosis/fibrosis and proliferation of tubular and en-
dothelial cells in various AKI models [86,87]. This beneficial 
effect was also found in experimental chronic kidney disease 
models, ameliorating epithelial-to-mesenchymal transition 
and preventing inflammatory cell infiltration [88,89]. MSCs 
that were engineered to overexpress miRNA-let7c could se-
lectively deliver miRNA-let7c to damaged kidney cells using 
exosomes, which led to protection from renal injury and 
decreased fibrosis in a unilateral ureteral obstruction model 
[90]. Nagaishi et al. [91] showed that MSC-derived renal tro-
phic factors including exosomes could alleviate albuminuria 
and immune cell infiltration into the kidneys in a diabetic 
nephropathy model. MSC-derived exosomes showed an 
antiapoptotic effect and protected tight junction structure 
in tubular epithelial cells. Intravenous injections of urinary 
stem cell-derived exosomes could also reduce urinary mi-
croalbumin excretion and prevent podocyte/tubular epithe-
lial cell apoptosis in diabetic rats [92]. 
Apart from MSCs, EVs from other origins have shown a 
renoprotective effect in animal kidney injury models. Exo-
somes derived from sera of animals after remote ischemic 
preconditioning could attenuate sepsis-induced renal 
damage, and this was mediated by the upregulation of exo-
somal miRNA-21 [93]. Dominguez et al. [94] showed that 
intravenous delivery of EVs from rat renal tubular cells could 
markedly reduce renal damage in recipients after ischemic 
insult. This group also showed that human renal exosomes 
can prevent ischemic renal injury in nude rats [95]. 
However, the clinical evidence of the renoprotective effect 
of EV therapy in humans is relatively scarce. Several prob-
lems limit the therapeutic application of EVs in humans; 
the low yield of EVs from cultured cells and premature EV 
isolation/ purification with a risk of contamination from 
other molecules with similar density [96,97]. Although sev-
eral studies have shown promising advances in EV isolation 
and purification, which is reviewed elsewhere [98], further 
efforts are needed to improve isolation efficiency and purity. 
Also, large-scale production is required for the therapeutic 
application of EVs in humans. Yang et al. [99] recently used 
a cellular nanoporation method to produce large-scale 
exosomes containing therapeutic mRNAs and targeting 
peptides. By using this strategy, they could produce a sig-
nificantly higher number of exosomes and exosomal mRNA 
transcripts compared with bulk electroporation and other 
exosome production strategies. Lastly, advanced techniques 
in the fine modulation of EV content using transfection or 
cell engineering is needed to deliver specific transcripts 
or protein composition into target cells. This will lead to a 
better understanding of the biological role of certain EVs in 
specific renal disease models and will broaden the thera-
peutic applicability of EVs in various renal diseases. 
Extracellular vesicles as potential therapeutic targets 
As we have mentioned, EVs can mediate the propagation 
of renal damage in septic, inflammatory, or thrombogenic 
conditions. Therefore, temporarily blocking the release and 
uptake of EVs can possibly alleviate tissue damage. Various 
pharmacologic agents including antiplatelet agents, statins, 
calcium channel blockers, and abciximab were found to 
negatively affect the process of EV release and uptake, which 
is reviewed elsewhere [1]. However, whether blocking the re-
lease and uptake of EVs can directly affect the disease course 
has not been fully investigated. A study by Mossberg et al. 
[100] showed that C1-inhibitor can significantly reduce the 
release of chemotactic kinin B1-receptor-positive endothelial 
microvesicles, suggesting it has therapeutic potential in in-
flammatory diseases. Further studies are required to under-
stand the clinical applicability of controlling EV interaction 
with recipient cells in systemic inflammatory conditions.  
Conclusions and perspectives 
EVs are involved in cell-to-cell communications within kid-
neys, mediating podocyte-tubulointerstitial/proximal-distal 
tubular/glomerulus-tubular crosstalk. EVs can either pro-
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vide physiological roles in renal repair and immunomodu-
lation or mediate pathological processes inducing throm-
bosis and inflammation. Recent studies have significantly 
improved our understanding of the roles of EVs in kidney 
physiology and pathology. However, most of the results are 
limited to descriptive transcriptomic/proteomic analysis 
and lack consistency as well as reliability. Stringent valida-
tion through clinical trials and large-scale cohort studies is 
necessary before entering into clinical application. Further 
optimization of EV isolation techniques and meticulous 
manipulation of the genetic materials or protein compo-
sitions of EVs are also necessary for clinical consideration. 
These efforts will extend our knowledge on the role of EVs 
in the development/ progression of kidney diseases and will 
broaden the clinical applicability of EVs as novel diagnostics 
and therapeutics of renal diseases. 
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